Efficacy of orally administered combination of moxidectin, sarolaner and pyrantel (Simparica Trio™) for the prevention of experimental Angiostrongylus vasorum infection in dogs

Table 2 Study 1: Angiostrongylus vasorum L1 counts in the feces and lung, percent efficacy, mean percent consolidated lung lobe area and mean total lung lesion severity scores by treatment group

Treatment	Moxidectin dose (µg/kg)^a	Fecal L1 counts^b		Lung L1 counts		Lung lesions^c
Treatment	Moxidectin dose (µg/kg)^a	Geometric mean	% Efficacy	Geometric mean	% Efficacy	% Lung consolidation	Mean total severity score
Placebo	0	0.141	–	235.7	–	45.3	15.3
Sarolaner + moxidectin + pyrantel	3	0.894	0	762.2	0	42.0	14.3
Sarolaner + moxidectin + pyrantel	12	0.075	46.8	58.0	75.4	16.1	9.9
Sarolaner + moxidectin + pyrantel	24	0.000	100	0.0	100	3.1	5.6

^aThe combination product-treated dogs received the exact moxidectin dose shown for each group, combined with 2 mg/kg sarolaner and 5 mg/kg pyrantel
^bFecal L1 counts (per gram feces) were conducted daily on samples collected before necropsy for 5–12 days
^cAt necropsy the percentage of consolidation for each of the six lung lobes was assessed and the mean % consolidation was calculated. The severity of the lesions on each lobe was scored on a scale from 0 to 3 (the maximum possible total score was 18)